Jakafi (ruxolitinib) — Medica

Initial criteria

• age ≥ 18 years
• patient has tried hydroxyurea, Pegasys (peginterferon alfa-2a), or Besremi (ropeginterferon alfa-2b-njft)

Approval duration

1 year